A CLINICAL INVESTIGATION OF CLOTRIMAZOLE (BAY B 5097) CREAM ON SKIN CANDIDIASIS

Abstract

An open, controlled, clinical investigation of a new antimycotic substance, Clotrimazole (Bay b 5097), comprising 30 patients with candidiasis confirmed the reliable therapeutic efficacy of the substance in the presentation of 1% cream. The excellent anti-fungal efficacy of the substance yielded impressive results in the patients treated. It is a definite advantage of Bay b 5097 thatits anti-mycotic spectrum is broader than that of other conventional topical agents. Side effects were described as erythema (1 time), not severe and not necessitating interruption or cessation of therapy.